|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
AU2002316811A1
(en)
|
2001-06-28 |
2003-03-03 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
|
CA2509755A1
(en)
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
JO2625B1
(en)
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
|
US20070051626A1
(en)
|
2003-09-26 |
2007-03-08 |
Chiho Itou |
Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
|
|
TR201906789T4
(tr)
|
2003-11-20 |
2019-05-21 |
Novo Nordisk As |
Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
|
|
EP2570133B1
(en)
|
2005-11-07 |
2016-03-23 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
CN101365432B
(zh)
|
2005-12-16 |
2011-06-22 |
默沙东公司 |
二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
|
|
RU2477286C2
(ru)
|
2007-01-05 |
2013-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
|
|
AU2008216265B2
(en)
|
2007-02-15 |
2014-04-03 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
JP5385266B2
(ja)
|
2007-06-15 |
2014-01-08 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
CN102027007A
(zh)
|
2008-05-16 |
2011-04-20 |
诺沃-诺迪斯克有限公司 |
长效的y2和/或y4受体激动剂
|
|
EP2477643A1
(en)
|
2009-09-18 |
2012-07-25 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
WO2011058165A1
(en)
|
2009-11-13 |
2011-05-19 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
CA3070513C
(en)
*
|
2010-05-05 |
2023-01-03 |
Boehringer Ingelheim International Gmbh |
A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
|
|
CN103068380A
(zh)
*
|
2010-06-17 |
2013-04-24 |
加州理工学院 |
用于调节激素的方法和系统以及相关的方法、剂和组合物
|
|
EP2548570A1
(en)
*
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
TWI495464B
(zh)
*
|
2013-02-08 |
2015-08-11 |
Univ Nat Taiwan |
苦味化合物於活化ｇｌｐ－１分泌之用途
|
|
US10835505B2
(en)
*
|
2018-06-11 |
2020-11-17 |
Aardvark Therapeutics, Inc. |
Oral pharmaceutical formulation for weight loss, diabetes and related disorders
|
|
WO2020102337A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Cymabay Therapeutics, Inc. |
Combination treatment of nafld and nash
|
|
AU2020354634A1
(en)
*
|
2019-09-25 |
2022-04-14 |
Aardvark Therapeutics Inc. |
Oral pharmaceutical immediate release composition and method of treatment for weight loss
|